Advances  	Advances  	 NNS	O
in  	in  	 IN	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
type  	type  	 NN	O
2  	2  	 CD	O
diabetes 	diabetes 	 NN	O
:  	:  	 :	O
GLP-1  	GLP-1  	 CD	B-NP
receptor  	receptor  	 NN	I-NP
agonists  	agonists  	 NNS	I-NP
and  	and  	 CC	O
DPP-4  	DPP-4  	 CD	B-NP
inhibitors  	inhibitors  	 CD	I-NP
Type  	Type  	 CD	O
2  	2  	 CD	O
diabetes  	diabetes  	 NN	B-NP
mellitus  	mellitus  	 NNS	I-NP
( 	( 	 -LRB-	O
T2DM 	T2DM 	 NNP	B-NP
)  	)  	 -RRB-	O
is  	is  	 VBZ	O
intrinsically  	intrinsically  	 VBN	O
connected  	connected  	 VBN	O
to  	to  	 TO	O
overweight  	overweight  	 VB	O
and  	and  	 CC	O
obesity 	obesity 	 NN	B-NP
.  	.  	 .	O
It  	It  	 PRP	O
is  	is  	 VBZ	O
a  	a  	 DT	O
complex  	complex  	 JJ	O
metabolic  	metabolic  	 JJ	B-NP
disorder  	disorder  	 NN	I-NP
that  	that  	 IN	O
predisposes  	predisposes  	 JJ	O
patients  	patients  	 NNS	O
to 	to 	 TO	O
,  	,  	 ,	O
and  	and  	 CC	O
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with 	with 	 IN	O
,  	,  	 ,	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
addition  	addition  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
triumvirate  	triumvirate  	 NN	B-NP
of  	of  	 IN	O
core  	core  	 JJ	O
defects  	defects  	 NNS	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
T2DM  	T2DM  	 NNP	O
( 	( 	 -LRB-	O
involvement  	involvement  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
pancreatic  	pancreatic  	 JJ	B-NP
beta  	beta  	 NN	I-NP
cell 	cell 	 NN	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
muscle 	muscle 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
liver 	liver 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
other  	other  	 JJ	O
mechanisms  	mechanisms  	 NNS	O
including  	including  	 VBG	B-NP
hyperglucagonemia 	hyperglucagonemia 	 NN	I-NP
,  	,  	 ,	O
accelerated  	accelerated  	 VBD	O
gastric  	gastric  	 JJ	B-NP
emptying 	emptying 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
incretin  	incretin  	 JJ	B-NP
deficiency 	deficiency 	 NN	I-NP
/ 	/ 	 CD	I-NP
resistance  	resistance  	 NN	I-NP
are  	are  	 VBP	O
also  	also  	 RB	O
involved 	involved 	 VBN	O
.  	.  	 .	O
This  	This  	 DT	O
has  	has  	 VBZ	O
led  	led  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
development  	development  	 NN	O
of  	of  	 IN	O
incretinbased  	incretinbased  	 JJ	B-NP
therapies 	therapies 	 NNS	I-NP
,  	,  	 ,	O
such  	such  	 JJ	O
as  	as  	 IN	O
glucagon-like  	glucagon-like  	 NNP	B-NP
peptide-1  	peptide-1  	 NNP	I-NP
( 	( 	 -LRB-	O
GLP-1 	GLP-1 	 NNP	B-NP
)  	)  	 -RRB-	O
receptor  	receptor  	 NN	B-NP
agonists  	agonists  	 NNS	I-NP
and  	and  	 CC	O
dipeptidyl  	dipeptidyl  	 CD	B-NP
peptidase-4  	peptidase-4  	 CD	I-NP
( 	( 	 -LRB-	O
DPP-4 	DPP-4 	 NNP	B-NP
)  	)  	 -RRB-	O
inhibitors 	inhibitors 	 NN	O
.  	.  	 .	O
These  	These  	 DT	O
newer  	newer  	 JJR	O
therapies  	therapies  	 NNS	O
have  	have  	 VBP	O
beneficial  	beneficial  	 JJ	O
effects  	effects  	 NNS	O
on  	on  	 IN	O
glycosylated  	glycosylated  	 FW	O
hemoglobin  	hemoglobin  	 FW	O
A1c  	A1c  	 FW	O
( 	( 	 -LRB-	O
HbA1c 	HbA1c 	 NNP	O
)  	)  	 -RRB-	O
levels 	levels 	 NNS	O
,  	,  	 ,	O
weight 	weight 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
pancreatic  	pancreatic  	 JJ	B-NP
beta-cell  	beta-cell  	 JJ	I-NP
function 	function 	 NN	I-NP
.  	.  	 .	O
